Source comparison
MOTS-c vs SLU-PP-332: Mechanism, Pathway, and Metabolic Outcome Comparison
Primary Mechanism AMPK activation via mitochondrial signalling Dual PPARγ/PPARδ agonism MOTS-c works within existing metabolic framework; SLU-PP-332 creates new metabolic conditions Mitochondrial Biogenesis Rate Moderate (31% increase in 6-week rodent studies)
This comparison does not assign a generated winner or score.
- Primary Mechanism
- AMPK activation via mitochondrial signalling
- Dual PPARγ/PPARδ agonism
- MOTS-c works within existing metabolic framework; SLU-PP-332 creates new metabolic conditions
- Mitochondrial Biogenesis Rate
- Moderate (31% increase in 6-week rodent studies)
- High (82% increase in 6-week rodent studies)
- SLU-PP-332 produces 2.6× greater mitochondrial expansion via direct PGC-1α upregulation
- Insulin Sensitivity Improvement
- 47% increase in skeletal muscle without weight change
- 44% glucose tolerance improvement with concurrent fat loss
- MOTS-c improves insulin signalling without adipose remodelling; SLU-PP-332 combines insulin sensitivity with fat mass reduction
- Endogenous vs Synthetic
- Naturally occurring mitochondrial-derived peptide
- Synthetic dual PPAR agonist
- MOTS-c mirrors physiological signalling; SLU-PP-332 bypasses natural receptor constraints
- Research Application Focus
- Aging, metabolic decline, endurance
- Metabolic reprogramming, obesity models, mitochondrial dysfunction
- Choose MOTS-c for physiological relevance; SLU-PP-332 for pharmacological intervention models
- Typical Dosing in Rodent Models
- 5–15 mg/kg i.p. or subcutaneous
- 10–30 mg/kg oral or i.p.
- Both require dose-response optimisation based on experimental endpoint